Data and Sample Sharing Policy (version 6.3)
1. Overview
The Mexico City Prospective Study (MCPS) (originally called ‘Proyecto Coyoacan’) is a blood-based prospective study of ~160,000 Mexican adults. Its main aims are to study the relevance of lifestyle, environmental, biochemical and genetic factors for major chronic diseases (e.g. stroke, heart disease, cancer, diabetes) in Mexican adults, to improve the prevention and treatment of these diseases.
Participants were recruited from 1998-2004. They were interviewed, had a range of physical measurements taken, gave 10 ml of blood (for long-term storage in Oxford of plasma and DNA-containing buffy coat), and gave permission for their subsequent health status to be tracked. Long-term follow-up for mortality is via electronic linkage to Mexico’s national death register. A resurvey of 10,000 surviving participants was carried out 2015-2019. This large research project is a longstanding collaboration between researchers from the National Autonomous University of Mexico (UNAM) in Mexico City, who conceived and established the study, and the Nuffield Department of Population Health in Oxford, who provided support during its inception and have continued to enhance it over the years.
Access to biological samples is limited by the small volume available. Consideration is given to collaborations that involve an extensive range of quality-controlled assays of all – or large numbers of – samples using high-throughput and cost-effective assay methods. The MCPS study group is actively seeking funding for assay strategies that will transform the available samples into accessible data for use by researchers in Mexico, UK and elsewhere.
At recruitment, as was consistent with standard practice at the time, the participants were not asked specifically for consent to data sharing with outside bodies. However, we understand that the consent was sufficient to permit the supply of pseudonymised data to bona-fide researchers of high scientific probity who have agreed to abide by the requirements described in this document and by any contractual arrangements with funders and external suppliers of the data relevant to the datasets.
Within the above constraints, the MCPS study group welcomes proposals for access to data from researchers in Mexico and around the world. This document describes the access policy and procedures. The process is summarised in this flow diagram:
Flow diagram of data request process
It has been developed in concordance with the general principles of data sharing promoted by various research organisations worldwide including the UK Research and Innovation’s Common Principles on Data Policy and the Data Access and Sharing Policy of the Nuffield Department of Population Health, University of Oxford.
|
Data |
Any MCPS study dataset, including summary datasets, baseline survey data, re-survey data, follow-up information, blood assay results, genomic and metabolomic data. |
|
Genomic Data |
Participant-level genotype, exome or whole genome sequence data. |
|
Data Sharing Agreement |
Agreement covering the terms of data access to a requestor of open access data. |
|
Collaboration Agreement
|
Agreement covering the terms of data access to a requestor working with a member of the MCPS study team in either Mexico or the UK. |
|
Access Agreement |
A collective term referring to either a data sharing agreement or a collaborative agreement. |
|
Open Access Data |
Data being made available to external bona fide researchers through this Data and Sample Sharing policy. |
|
Restricted Data |
Data stored in the MCPS data repository which has limitations placed on its use or wider distribution. |
|
Requestor |
An individual or group of researchers seeking access to data and/or samples from the MCPS. |
|
Data User |
An individual or group of researchers that has been granted access to data and/or samples from the MCPS. |
As the MCPS has information on many different exposures and health outcomes over a period of years, a wide range of investigators should be involved in determining which questions to address and how best to address them. As data custodian, the MCPS group must maintain the integrity of the database for future use and regulate data access. Data can be released outside the MCPS research group only with appropriate security safeguards and approvals. This policy on data access is based on the need to:
- Protect participants and act within the scope of their signed consent.
- Ensure compliance with all laws and regulations which apply to its use, storage and disposal of the data and/or samples.
- Ensure high quality research is fostered that will advance knowledge. Applications that include Mexican collaborators are particularly welcome since they would help to develop and strengthen the research capacity of local investigators.
- Ensure that the data security and participant confidentiality are maintained.
- Support local capacity building. There is a desire that the data from the MCPS are not only used to generate important research findings but also to help to build research capacity locally.
- Provide academic return and training for the investigators developing the study, in particular for doctoral students and early career researchers who are developing their scientific skills while working on the cohort.
3.1. Key components of this Data and Sample Sharing Policy:
Collaborations
The MCPS research group is actively seeking and responding to requests for scientific collaborations on specific projects, especially when framed in ways that help strengthen Mexican research capacity. This model of facilitated collaboration with external researchers is adopted where it can increase the value and quality of the data. Collaborations are governed by a separate Collaboration Agreement, which: (i) identifies a dedicated project lead from within the MCPS group in either Mexico and/or the UK; (ii) details arrangements for co-authorship or papers; (iii) covers intellectual property issues; and (iv) details financial commitments where appropriate.
Open Access Data Availability
Before data is approved for any analysis, relevant members of the MCPS team responsible for generating the data must first undertake required cleaning, processing, quality control and integration. As soon as the data are clean, they will be made immediately available for open access sharing with researchers applying from within a Mexican institution, as long as the proposed project does not overlap significantly with projects already being conducted by the Mexico or Oxford-based investigators (see Completed and Protected Projects). This period of exclusive access for Mexican researchers will be for 2 years, after which the datasets will be made available for open access sharing with any bona-fide researcher worldwide (see Data Available for Sharing).
Independent Oversight of Access
Initial decisions on data requests are taken by the MCPS team. The Nuffield Department of Population Health Data Access Oversight Committee provides further scrutiny and governance advice where necessary. A requestor can appeal to this committee if they disagree with a study decision on access.
Protecting the Identity of Participants
Safeguards are maintained to ensure the anonymity and confidentiality of participants’ data. Researchers will need to enter a legal agreement not to make any attempt to identify participants, and the data provided to researchers will not contain any personally identifiable variables (i.e. every data set provided will be “pseudonymised” with uniquely encrypted participant identifiers [PIDs]).
Data Security
All MCPS data is held on secure servers in a central data repository that is compliant with internationally recognised information governance standards. A data management team acts as gatekeepers and ensure that any shared data is delivered though a secure data delivery system and in an appropriate format.
Sample Preservation and Access
Only 10 ml of blood was taken at baseline and resurvey from each participant, which, in each instance, was divided into one buffy coat sample and two to three plasma samples that are stored in Oxford. At resurvey, a urine sample was collected from just under half the participants (from the latter part of the recruitment period). Given the very limited amount of these depletable resources, access to these samples needs to be carefully controlled. Consequently, rather than assay samples on a nested case-control basis (which is cost-effective for studying a particular condition but not for a resource that is to be used to study many different conditions by different researchers), assays of the samples from all participants is far preferable. Such a strategy maximises the information available to researchers while minimising sample depletion and facilitating different comparisons across the cohort since the assay methodology and quality control would be consistent. Suggestions for particular assays to be included are welcomed, and all assay values will become part of the available dataset. In general (as is the case in UK Biobank), it is not expected that requests for direct access to samples will be agreed to by the MCPS Access Committee.
Fees for data access
Open access data is available free of charge to applicants from low and middle income countries. Researchers in high-income countries will incur a data access charge for each data application. The charge ranges from £2500 GBP to £7500 GBP and is dependent on the data required (see Data Access Charges). It must be paid prior to data release. The charge contributes to the administrative costs incurred in managing and reviewing the application, and in preparing datasets. For applications that require Genomic Data the charge includes Amazon Web Services (AWS) credits to the value of $1000 USD. These credits are used in the DNAnexus platform against the costs of compute and egress of results. Costs beyond these credits will be charged to the applicant on an annual basis. Researchers from low and middle income counties using DNAnexus will not be charged for compute and egress as long as costs are considered reasonable to complete the project.
Collaborating researchers may also be required to cover the costs of administering the data sharing (including legal fees if applicable), retrieving, processing and sending the data or samples. Estimated costs for a particular request will be provided during the development of the project proposal.
Potential collaborators and data requestors should first contact MCPS investigators or review this website (including previous MCPS publications), the MCPS Data Showcase and the MCPS Variant Browser and to gain an understanding of the available study data and of projects that have previously been completed or are under way. The MCPS Data Showcase aims to present the data available from the study for health-related research in a comprehensive and concise way, and to provide additional information for researchers considering applying to use the resource.
4.1 Collaboration requests
Researchers who are interested in collaborating on projects with MCPS researchers in Mexico or the UK are encouraged to approach the MCPS group informally in the first instance by email or to contact relevant MCPS investigators to discuss research ideas and feasibility. Enquiries should include a project title and brief outline of the research project and the relevant data of interest. Each project will require a co-investigator from within the MCPS group who has a common interest in the project and relevant or complementary research expertise. Once identified, the collaborator and the co-investigator will co-develop a research proposal which will then be reviewed by the MCPS Access Committee.
4.2 Open Access Data requests
Registration/eligibility
All open access data requestors are first required to complete the MCPS Data Access Registration form (also available in Spanish). Requestors should be employees of a recognised academic institution, health service organisation or charitable research organisation with experience in medical research. They should be able to clearly demonstrate, through their peer reviewed publications in the area of interest, their ability to conduct independent research.
Submission of a data request
Once approved, data requestors will be sent an MCPS Data Request Form and will need to return the completed form to mcps-access@ndph.ox.ac.uk. This form requires the requestor to provide: a project title and abstract; scientific rationale/methodology; anticipated outputs and project timeline. Additional questions cover ethical issues, collaborators/research team, funding support and data security, and the data variables they would like to receive.
Review of a data request
Open access data requests will initially be assessed by the MCPS study investigators. Each application will be considered on its individual merit. If necessary, independent peer review will be sought. Approved projects will: (i) have clearly defined objectives; (ii) include a sound methodology that is likely to generate meaningful results; (iii) be based on an appropriate and available selection of data; (iv) have clearly defined timelines and outputs (such as one-two papers in peer-reviewed journals). Projects that overlap significantly with those underway by MCPS researchers may be rejected.
The MCPS team aims to review and respond to data requests within two to four weeks. A requestor can appeal to the Nuffield Department of Population Health’s Independent Data Access Oversight Committee if their request is denied by the project team using this contact us form.
Once proposals are approved the following conditions and undertakings are required as conditions of access:
Data Sharing Agreement
Before any data are shared a signed sharing agreement must be in place between the requestor’s institution and the University of Oxford. This agreement will be sent to the requestor once their application is approved, and will include a copy of the approved project proposal as a schedule.
Signing Authority
Requestors should be acting as members of a recognised academic institution, research organisation or health organisation. Their request should come from a recognised email domain. Their organisation should have formal policies and procedures (i.e. IG Toolkit, ISO 27001 certification or System Level Security Policy assessment) to comply with any legal, ethical or data protection constraints and to ensure that the dataset is stored securely and used responsibly.
Ethics and Research Governance Approval
Where applicable Ethics Committee approval for the research is the responsibility of the requestor. The requestor, in conjunction with study investigators, may also need to obtain approval from the Research Ethics Committees responsible for the MCPS. Local Research Governance approval and R&D approvals, if required, are the responsibility of the requestor. Approvals will need to be in place before any data are shared.
Limitations on Use
The data will be used for the purposes of medical research only and within the constraints of the consent under which the data were originally gathered, and of any contractual agreements between the MCPS and its funders or external data sources. Access will be permitted only for research that is consistent with the originally-submitted project description, has been ethically and scientifically approved by appropriate independent reviewers and where the use of the data will be for the demonstrable benefit of health and/or social care. Data supplied may only be shared with requestors named at the time of the original application or in subsequent applications and specified in the Access Agreement or later amendments. Data from the collection cannot be shared with individuals outside the requestor’s research group without formal approval by the MCPS Principal Investigators.
Identifying Data
The data provided to researchers will not contain any personally identifiable variables. Data sets will be ‘pseudonymised’ with encrypted participant identifiers (PIDs). The Access Agreement will contain confidentiality undertakings to further safeguard participants' privacy. Recipients must agree not to link the pseudonymised data provided with any other data set without permission. Recipients must not attempt to identify any individual from the data provided. Should recipients believe that they have inadvertently identified any individual, they must not record this, share the identification with any other person or attempt to contact the individual.
Intellectual Property
All Intellectual Property (IP) rights in the data are and shall remain at all times the property of UNAM and the University of Oxford. All Arising IP shall vest in and be owned by the requestors. The requestors will cover any cost for the protection of Arising IP. The requestors shall promptly disclose any such Arising IP in writing to the Principal Investigators. UNAM and the University of Oxford will be granted rights to use all Arising IP for academic and research purposes, including research involving projects funded by third parties provided that those parties gain or claim no rights to such Arising IP.
Payment of Access Charges
Data requestors from institutions in high-income countries are expected to pay access charges to contribute to the administrative cost to the study of reviewing the application and preparing data for sharing, etc. Where these are applied, no data will be provided to the data requestor until or unless the access charges are received in full.
Data Release and Delivery
Once the proposal is approved and the Access Agreement signed, phenotypic data and its documentation will be generated in CSV (or any other pre-specified) format, encrypted and released in a secure manner. The genomic data will be shared by granting access to an online research analysis platform enabled by DNAnexus technology and powered by AWS, where researchers will be able to access both the genomic and non-genomic data, perform their analyses and download their results. Access to MCPS data via the DNAnexus platform will be until at least March 2029.
Publicity and Dissemination
The MCPS team reserves the right to publish the title, the names(s) and affiliations(s) of the Chief Investigator(s), a lay summary and a scientific abstract of each piece of collaborative research for which access to the resource has been granted, before identification or publication of results. Requestors who do not wish details of their study to be openly available need to state this in their data request and give the reason. The requestor shall not use the name or any trademark or logo of UNAM or the University of Oxford in any press release or product advertising, or for any other commercial purpose, without prior written consent.
PAyment of dnanexus charges
Open access data users from high-income countries working on DNAnexus will need to pay any DNAnexus charges above the $1,000 USD AWS credits granted on approval of their application. Invoices for these charges will be sent in April of each year and failure to pay these charges in a timely manner may result in access being removed.
Authorship and Approvals
Access Agreements will specify expectations regarding authorship and acknowledgements on research outputs. Collaborations require at least one co-author from the MCPS study group. For Open Access Agreements no authorship from the MCPS team is required, but requestors are nevertheless asked to submit proposed publications to the MCPS team for review not less than 30 days in advance of the submission for publication.
Publications and Open Access
All publications of the results in a peer-reviewed journal, or as a scholarly monograph or book chapter, must be made available from PubMed Central and Europe PubMed Central as soon as possible and no later than six months from the date of final publication. Journal requirements for data release and deposition that may be requested following publication of an article must be discussed with and approved by the MCPS Principal Investigators prior to submission of a manuscript.
Integration of the Data
After completion of work using released MCPS data, the original dataset as well as any derived dataset and/or variables generated during the research must be returned to the MCPS central data repository for archiving and/or merging with the main database for future use. If considered appropriate, the MCPS staff may carry out independent checks and/or validation of the data and results to ensure the continued data integrity and reliability of the study findings.
Monitoring and Accountability
The data requestor is required to submit annual reports and any other information reasonably requested to evidence the work undertaken in connection with the proposed project. If there is substantial deviation or change in the planned use of the data, further approval will be needed. If there is substantial delay or difficulty in completing the planned research, the MCPS team will have the right, after consultation with the Nuffield Department of Population Health Data Access Oversight Committee, to terminate the work if in its view there is little chance that the problem will be rectified. Under such circumstances, all data that have been provided must be deleted and a deletion certificate provided.
Details of data - available to researchers worldwide
For full details of available data please review the online MCPS Data Showcase. The Showcase displays all the data types currently available, in a grouped format (i.e. not at the individual participant level), along with further information about each data field (for example, background information about how measures were taken). Genetic variation can be viewed using the MCPS online Variant Browser.
Baseline data (1998-2004)
Available for 159,517 participants
|
Month and year of recruitment Socio-demographic
Lifestyle characteristics
|
Prior diseases and medication Reproductive history (women)
Physical measurements
|
Blood samples
|
Resurvey data (2015-2019)
Available for 10,143 participants. Similar data to that collected at baseline plus:
|
Additional questionnaire data
|
Additional samples
|
Additional measurements
- Bioimpedance (fat mass, fat free mass, muscle mass, muscle score, bone mass, body water, degree of obesity, visceral fat rating, basal metabolic rate, metabolic age, Rohrer’s index)
- Pulse rate
Baseline NMR metabolomic data using the Nightingale Health platform
First release: 40,297 participants
|
14 Lipoprotein subclasses
|
Lipoprotein mean particle sizes and apolipoproteins
|
Cholines and glycolysis-related
|
|
7 Lipid measures for each subclass
|
Fatty acids
|
Amino acids
|
|
Ketone bodies, inflammation and kidney function
|
||
Genomic Data
Described fully in Ziyatdinov et al. 2023
|
Genome–wide genotyping with the Illumina Global Screening Array (GSA) version 2 • Non-filtered dataset (140,831 participants) • Quality controlled dataset (138,511 participants) Whole Exome Sequencing (WES) • Non-filtered dataset (141,046 participants) Whole Genome Sequencing (WGS) • Non-filtered dataset (9950 participants) • Phased WGS Imputation Reference Panel (MCPS10k)9,948 whole genome sequenced phased samples • Total of 134,337,444 variants distributed across 22 autosomes and chromosome X • Data available in four file formats. TopMed Imputed • Non-filtered dataset (140,831 participants) |
Mortality data (up to 30th September 2022)
- Date of death
- ICD-10 underlying cause
- ICD-10 contributory causes
- Timing/duration of diseases
- Location of death
- Seen by doctor before death
Apo A1=apolipoprotein A1; Apo B=apolipoprotein B; HDL=high density lipoproteins; HDL−D=high density lipoprotein particle diameter; IDL=intermediate density lipoproteins; L=large; LDL=low density lipoproteins; LDL−D=low density lipoprotein particle diameter; M=medium; S=small; VLDL=very low density lipoproteins; VLDL−D=very low density lipoprotein particle diameter; XL=very large; XS=very small; XXL=extremely large.
Additional data currently available only to researchers in Mexico
NMR metabolomic data using the Nightingale Health platform
Second release: 152,833 participants at baseline and 9657 participants at resurvey
All metabolites as listed for the first release plus Aceto-acetate, Clinical LDL-C, and, Glycine and Pyruvate.
To date, the MCPS research teams in Oxford and UNAM have focused on studying the relevance to cause-specific mortality of major disease risk factors, including diabetes,1-5 adiposity,6-10 blood pressure,11,12 smoking,13 low levels of education14 and alcohol consumption.15 We have also published several cross-sectional analyses related to these16-19 and other cardiometabolic risk factors including lipids and other biomarkers.20-21 In addition, current analyses (anticipated for publication in 2025/6) will report the relevance of physical activity and renal function to cause-specific mortality, as well as the combined relevance of these major disease risk factors to cardiovascular risk. If you are interested in studying any of these risk factors we recommend that you review these published papers (or contact us) to see what has already been, or soon will be, published from the study.
In addition, several areas of research are currently being explored by PhD students or researchers at Oxford and UNAM, and are therefore considered protected until the completion of the project. These include, but are not limited to, studying the genetics of diabetes, kidney function, adiposity, blood pressure, cognitive function and blood lipids, Mendelian randomisation studies of these phenotypes, and use of polygenic risk scores for predicting cardio-metabolic mortality. We are particularly focused on studying genetic admixture and/or local ancestry in the context of cardiometabolic traits. Applications for projects that overlap significantly with protected projects may therefore require further discussion before approval.
External projects (open access and collaborations) that have been approved and have an access agreement in place are listed below (last updated 22 October 2025).
|
Principal investigator: Dr Christina Magnussen |
|
Principal investigator: Dr Omar Yaxmehen Bello-Chavolla |
|
Principal Investigator: Dr Omar Yaxmehen Bello-Chavolla |
|
Principal Investigator: Dr Omar Yaxmehen Bello-Chavolla |
|
Principal Investigator: Dr Omar Yaxmehen Bello-Chavolla |
|
Principal Investigator: Dr Omar Yaxmehen Bello-Chavolla |
|
Principal Investigator: Dr Omar Yaxmehen Bello-Chavolla |
|
Principal Investigator: Dr Omar Yaxmehen Bello-Chavolla |
|
Principal Investigator: Dr Omar Yaxmehen Bello-Chavolla |
|
Principal Investigator: Dr Omar Yaxmehen Bello-Chavolla |
|
Principal Investigator: Dr Omar Yaxmehen Bello-Chavolla |
|
Principal Investigator: Dr Omar Yaxmehen Bello-Chavolla |
|
Principal Investigator: Dr Omar Yaxmehen Bello-Chavolla |
|
Principal Investigator: Dr Omar Yaxmehen Bello-Chavolla |
|
Principal Investigator: Dr Omar Yaxmehen Bello-Chavolla |
|
Principal Investigator: Dr Omar Yaxmehen Bello-Chavolla |
|
Principal Investigator: Dr Omar Yaxmehen Bello-Chavolla |
|
Principal Investigator: Dr Omar Yaxmehen Bello-Chavolla |
|
Principal Investigator: Dr Lorena Orozco |
|
Principal Investigator: Dr Yanink Caro-Vega |
|
Principal Investigator: Dr Mashaal Sohail |
|
Principal Investigator: Dr Mashaal Sohail |
|
Principal Investigator: Dr Gary O'Donovan |
|
Principal Investigator: Dr Gerson Ferrari |
|
Principal Investigator: Dr Claudia Gonzaga-Jauregui |
|
Principal Investigator: Dr Cristopher Van Hout |
|
Principal Investigator: Dr Claudia Gonzaga-Jauregui |
|
Principal Investigator: Dr Claudia Gonzaga-Jauregui |
|
Principal Investigator: Dr Claudia Gonzaga-Jauregui |
|
Principal Investigator: Dr Claudia Gonzaga-Jauregui |
|
Principal Investigator: Dr Enrique Gomez-Figueroa |
|
Principal Investigator: Dr Adrian Soto-Mota |
|
Principal Investigator: Dr Vicente Diego Ortega-Del Vecchyo |
|
Principal Investigator: Dr Yang Luo |
|
Principal Investigator: Dr Cristopher Van Hout |
|
Principal Investigator: Dr Claudia Gonzaga-Jauregui |
|
Principal Investigator: Dr Claudia Gonzaga-Jauregui |
|
Principal Investigator: Dr Osvaldo Máximo Mutchinick Baringoltz |
|
Principal Investigator: Dr Omar Yaxmehen Bello-Chavolla |
|
Principal Investigator: Dr Gary O'Donovan |
|
Principal Investigator: Dr Lorena Orozco |
|
Principal Investigator: Dr Fanny Petermann-Rocha |
|
Principal Investigator: Dr Catalina Medina Garcia |
|
Principal Investigator: Dr Malaquías López Cervantes |
|
Principal Investigator: Prof Peter Visscher |
|
Principal Investigator: Prof Gregorio Obrador Vera |
|
Principal Investigator: Dr Elizabeth Atkinson |
|
Principal Investigator: Dr Gary O'Donovan |
|
Principal Investigator: Evelia Apolinar-Jiménez |
|
Principal Investigator: Dr Gerson Ferrari |
|
Principal Investigator: Prof Janitza L. Montalvo-Ortiz |
|
Principal Investigator: Dr Adrian Rubli |
|
Principal Investigator: Dr Javier Calvo Marin |
|
Principal Investigator: Dr Gerson Ferrari |
|
Principal Investigator: Dr Carolina Ochoa Rosales |
|
Principal Investigator: Dr Gerson Ferrari |
|
Principal Investigator: Valerie Gunchick |
|
Principal Investigator: Dr Carolina Ochoa Rosales |
|
Principal Investigator: Dr Josep Mercader |
|
Principal Investigator: Dr Josep Mercader |
|
Principal Investigator: Dr Fanny Petermann-Rocha |
|
Principal Investigator: Dr Catalina Medina Garcia |
|
Principal Investigator: Prof Janitza L. Montalvo-Ortiz |
|
Principal Investigator: Prof Paolo Boffetta |
|
Principal Investigator: Dr Gretchen Saunders |
|
Principal Investigator: Dr Steven Hageman |
|
Principal Investigator: Rodrigo Garcia-Cerde |
|
Principal Investigator: Dr Enrique Gomez-Figueroa |
|
Principal Investigator: Dr Ruth Selene Fuentes Garcia |
|
Principal Investigator: Dr Lorena Orozco |
|
Principal Investigator: Dr Gerson Ferrari |
|
Principal Investigator: Dr Gerson Ferrari |
|
Principal Investigator: Dr Edgar Denova Gutierrez |
|
Principal Investigator: Dr Fabiola Mabel Del Razo Olvera |
|
Principal Investigator: Dr Ana Lucía Yáñez Félix |
|
Principal Investigator: Dr Wenjian Bi |
|
Principal Investigator: Dr Xiang Gao |
|
Principal Investigator: Duncan Robertson |
|
Principal Investigator: Dr Daniel Benjamín Elías López |
|
Principal Investigator: Prof Johannes Kettunen |
|
Principal Investigator: Dr Omar Yaxmehen Bello-Chavolla |
|
Principal Investigator: Dr Omar Yaxmehen Bello-Chavolla |
|
Principal Investigator: Dr Ana Luisa Sosa Ortiz |
|
Principal Investigator: Dr Stefan Blankenburg |
|
Principal Investigator: Dr Stefan Blankenburg |
|
Principal Investigator: Dr Cristopher Van Hout |
|
Principal Investigator: Prof Johannes Kettunen |
|
Principal Investigator: Prof Inês Barroso |
References
- Alegre-Díaz, Herrington, López-Cervantes et al. Diabetes and cause-specific mortality in Mexico City. New Engl J Med 2016; 375: 1961-1971.
- Herrington, Alegre-Díaz, Wade et al. Effect of diabetes duration and glycaemic control on 14-year cause-specific mortality in Mexican adults: a blood-based prospective cohort study. Lancet Diab Endocrinol 2018; 6: 455-463.
- Bragg, Kuri-Morales, Berumen et al. Diabetes and infectious disease mortality in Mexico City. BMJ Open Diab Res Care 2023; 11: e003199.
- Bragg, Kuri-Morales, Trichia et al. Type 2 diabetes and cause-specific mortality in Mexico City: a Mendelian randomization analysis. Lancet Reg Health Am 2025; 45: 101082.
- Fermín-Martínez, Yaxmehen Bello-Chavolla, Daniel Paz-Cabrera et al. Prediabetes and risk of all-cause and cause-specific mortality: a prospective study of 114,062 adults in Mexico City. J Clin Endocrinol Metab 2025 dgaf225.
- Gnatiuc, Alegre-Díaz, Wade et al. General and abdominal adiposity and mortality in Mexico City: prospective study of 150 000 Adults. Ann Int Med 2019; 171: 397-405.
- Gnatiuc, Tapia-Conyer, Wade et al. Abdominal and gluteo-femoral markers of adiposity and risk of vascular-metabolic mortality in a prospective study of 150 000 Mexican adults. Eur J Prev Cardiol 2022: 29(5); 730-8.
- Alegre-Díaz, Friedrichs, Ramirez-Reyes et al. Body mass index and COVID-19 mortality: prospective study of 120 000 Mexican adults. Int J Epidemiol 2022;51(5):1698-700.
- Gnatiuc Friedrichs, Wade, Alegre-Díaz et al. Body composition and risk of vascular-metabolic mortality risk in 113 000 Mexican men and women without prior chronic disease. J Am Heart Assoc. 2023 Jan 25: e028263.
- Gnatiuc Friedrichs, Kuri-Morales, Trichia et al. A Mendelian Randomization study of the effect of body mass index on 52 causes of death among 125,000 Mexican adults with admixed ancestry. Int J Epidemiol 2025: 54; 4: dyaf110.
- Tapia-Conyer, Alegre-Díaz, Gnatiuc et al. Association of blood pressure with cause-specific mortality in Mexican adults. JAMA Network Open. 2020; 3: e201814.
- Turner, Kuri-Morales, Alegre-Díaz, et al. Blood Pressure and Mortality in Mexico City: A Mendelian Randomization Study. Hypertension. Published online September 17, 2025. doi:10.1161/HYPERTENSIONAHA.125.25348.
- Thomson, Tapia-Conyer, Lacey et al. Low-intensity daily smoking and cause-specific mortality in Mexico: prospective study of 150,000 adults. Int J Epidemiol 2021; 50: 955-64.
- Addey, Alegre-Díaz, Bragg et al. Educational and social inequalities and cause-specific mortality in Mexico City: a prospective study. Lancet Public Health 2023; 8(9): e670-e679.
- Trichia, Alegre-Díaz, Aguilar-Ramirez et al. Alcohol and mortality in Mexico: prospective study of 150 000 adults. Lancet Pub Health 2024; 9(11): e907-e915.
- Kuri-Morales, Emberson, Alegre Díaz et al. The prevalence of chronic diseases and major disease risk factors at different ages among 150 000 men and women living in Mexico City: cross-sectional analyses of a prospective study. BMC Public Health 2009, 9: 9.
- Aguilar-Ramirez, Alegre-Díaz, Gnatiuc et al. Changes in the diagnosis and management of diabetes in Mexico City between 1998-2004 and 2015-19. Diabetes Care 2021;44(4): 944-51
- Gnatiuc, Alegre-Díaz, Halsey et al. Adiposity and blood pressure in 110 000 Mexican adults. Hypertension 2017; 69: 608-14.
- González-Carballo, Kuri-Morales, Chiquete et al. Cognitive impairment at older ages among 8000 men and women living in Mexico City: cross-sectional analyses of a prospective study. BMC Public Health 2024; 24: 3620.
- Aguilar-Ramirez, Alegre-Díaz, Herrington et al. Association of kidney function with NMR-quantified lipids, lipoproteins, and metabolic measures in Mexican adults. J Clin Endocrinol Metab 2021; 106(10): 2828-39.
- Aguilar-Ramirez, Herrington, Alegre-Díaz et al. Adiposity and NMR-measure lipid and metabolic biomarkers among 30,000 Mexican adults. Commun Med 2022; 2: 143.
Data access charges apply to open access projects from researchers based in high-income countries. Tier 2 and Tier 3 charges include $1000 USD worth of AWS credits for use on DNAnexus (the online platform for analysing MCPS genomic data). Costs above $1000 USD will be charged to the researcher.
| Description | Tier 1 | Tier 2 | Tier 3 |
|
Core Data
|
YES
|
YES |
YES |
|
Genotype data
|
YES |
YES |
|
|
Sequencing Data
|
YES |
||
| Data access charges (access guaranteed until at least March 2029) |
|||
| Low- and Middle-income countries | No charge | No charge | No charge |
| High-income countries | £2500 | £5000 | £7500 |
Prices are inclusive of VAT
List of low- and middle-income Countries that are exempt from data access charges
| Afghanistan | Ghana | Nigeria |
| Albania | Grenada | North Macedonia |
| Algeria | Guatemala | Pakistan |
| American Samoa | Guinea | Panama |
| Angola | Guinea-Bissau | Papua New Guinea |
| Argentina | Guyana | Paraguay |
| Armenia | Haiti | Peru |
| Azerbaijan | Honduras | Philippines |
| Bangladesh | India | Romania |
| Belize | Indonesia | Rwanda |
| Benin | Iraq | Samoa |
| Bhutan | Jamaica | São Tomé and Principe |
| Bolivia | Jordan | Senegal |
| Bosnia and Herzegovinia | Kazakhstan | Serbia |
| Botswana | Kenya | Sierra Leone |
| Brazil | Kiribati | Solomon Islands |
| Bulgaria | Kosovo | Somalia |
| Burkina Faso | Kyrgyz Republic | South Africa |
| Burundi | Lao PDR | South Sudan |
| Cabo Verde | Lebanon | Sri Lanka |
| Cambodia | Lesotho | St. Lucia |
| Cameroon | Liberia | St. Vincent and the Grenadines |
| Central African Republic | Libya | Sudan |
| Chad | Madagascar | Suriname |
| Colombia | Malawi | Tajikistan |
| Comoros Congo, Dem Rep. | Malaysia | Tanzania |
| Congo Rep | Maldives | Thailand |
| Costa Rica | Mali | Timor-Leste |
| Côte d'Ivoire | Marshall Islands | Togo |
| Djibouti | Mauritania | Tonga |
| Dominica | Mauritius | Tunisia |
| Dominican Republic | Mexico | Turkey |
| Ecuador | Micronesia, Fed. Sts | Turkmenistan |
| Egypt, Arab Rep. | Moldova | Tuvalu |
| El Salvador | Mongolia | Uganda |
| Equatorial Guinea | Montenegro | Ukraine |
| Eritrea | Morocco | Uzbekistan |
| Eswatini | Mozambique | Vanuatu |
| Ethiopia | Myanmar | Vietnam |
| Fiji | Namibia | West Bank and Gaza |
| Gabon | Nepal | Yemen, Rep |
| Gambia, The | Nicaragua | Zambia |
| Georgia | Niger | Zimbabwe |